|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.60 HKD | -1.08% |
|
+7.92% | +64.72% |
| 15/04 | RemeGen Receives $650 Million Upfront Payment From AbbVie Under Licensing Agreement | MT |
| 13/04 | RemeGen Drug Approved For Cancer Indication | MT |
| Capitalization | 7.33TCr 8.42TCr 1.07TCr 912.08Cr 835.99Cr 793.9Cr 1.47TCr 1LCr 1.5TCr 9.81TCr 3.86TCr 48TCr 4.03TCr 3.95TCr 1,70400Cr | P/E ratio 2026 * |
16.2x | P/E ratio 2027 * | 78.1x |
|---|---|---|---|---|---|
| Enterprise value | 7.05TCr 8.1TCr 1.03TCr 877.83Cr 804.59Cr 764.08Cr 1.41TCr 96TCr 1.44TCr 9.44TCr 3.71TCr 46TCr 3.88TCr 3.8TCr 1,64000Cr | EV / Sales 2026 * |
9.88x | EV / Sales 2027 * | 15.2x |
| Free-Float |
55.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.08% | ||
| 1 week | +7.92% | ||
| Current month | +23.80% | ||
| 1 month | +27.25% | ||
| 3 months | +26.17% | ||
| 6 months | +28.22% | ||
| Current year | +64.72% |
| 1 week | 107.8 |  | 123.1 |
| 1 month | 85.95 | | 123.1 |
| Current year | 69.7 | | 123.1 |
| 1 year | 34.5 | | 126.6 |
| 3 years | 10.2 | | 126.6 |
| 5 years | 10.2 | | 145.5 |
| 10 years | 10.2 | | 149.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Min Fang
CEO | Chief Executive Officer | 64 | 04/07/2008 |
Shao Jing Tong
DFI | Director of Finance/CFO | 55 | 28/09/2023 |
Qing Kai Wen
SEC | Corporate Secretary | 60 | 11/05/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Jian Min Fang
BRD | Director/Board Member | 64 | 04/07/2008 |
Jian Lin
BRD | Director/Board Member | 71 | 04/07/2008 |
Liqiang Wang
BRD | Director/Board Member | 56 | 11/05/2020 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.49% | 0% | 33,076 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.08% | +7.92% | +256.16% | +139.11% | 1.1TCr | |
| -1.42% | +4.52% | +34.99% | +104.04% | 5.27TCr | |
| +0.37% | -5.63% | +88.76% | +27.68% | 4.41TCr | |
| -1.15% | -5.50% | +96.59% | +706.89% | 3.12TCr | |
| +2.21% | +8.78% | +6.51% | -13.02% | 2.6TCr | |
| -0.12% | +25.41% | +2.07% | +1,479.87% | 1.95TCr | |
| -0.39% | +0.85% | +73.56% | -31.77% | 1.89TCr | |
| -2.72% | +6.60% | +77.09% | +239.26% | 1.78TCr | |
| -1.61% | -1.14% | +37.44% | -36.15% | 1.75TCr | |
| -2.69% | +3.86% | +77.30% | - | 1.55TCr | |
| Average | -0.86% | +5.50% | +75.05% | +290.66% | 2.54TCr | |
| Weighted average by Cap. | -0.69% | +3.57% | +64.53% | +259.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 713.83Cr 819.92Cr 104.71Cr 89Cr 81Cr 77Cr 142.94Cr 9.74TCr 145.99Cr 955.47Cr 375.78Cr 4.7TCr 392.76Cr 384.62Cr 17TCr | 463.26Cr 532.1Cr 68Cr 58Cr 53Cr 50Cr 93Cr 6.32TCr 95Cr 620.07Cr 243.87Cr 3.05TCr 254.89Cr 249.6Cr 11TCr |
| Net income | 357.36Cr 410.47Cr 52Cr 44Cr 41Cr 39Cr 72Cr 4.88TCr 73Cr 478.33Cr 188.13Cr 2.35TCr 196.63Cr 192.55Cr 8.31TCr | 74Cr 85Cr 11Cr 9.23Cr 8.46Cr 8.04Cr 15Cr 1.01TCr 15Cr 99Cr 39Cr 488.26Cr 41Cr 40Cr 1.73TCr |
| Net Debt | -275.18Cr -316.07Cr -40Cr -34Cr -31Cr -30Cr -55Cr -3.75TCr -56Cr -368.32Cr -144.86Cr -1.81TCr -151.41Cr -148.27Cr -6.4TCr | -288.16Cr -330.99Cr -42Cr -36Cr -33Cr -31Cr -58Cr -3.93TCr -59Cr -385.71Cr -151.7Cr -1.9TCr -158.55Cr -155.26Cr -6.7TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | 118.60 $ | -1.08% | 31,39,217 |
| 17/26/17 | 119.90 $ | +1.61% | 37,63,107 |
| 16/26/16 | 118.00 $ | -0.25% | 46,36,141 |
| 15/26/15 | 118.30 $ | +9.13% | 70,99,398 |
| 14/26/14 | 108.40 $ | -1.36% | 26,65,097 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 9995 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition